Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
$22.16
-$0.05(-0.51%)
At close: 4:00 PM EST
$22.16
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$6.11 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)694.71K
Market Cap
$1.27B
Enterprise Value$958.61M
Total Cash (Recent Filing)$343.19M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
May 14, 2026EPS Estimate
-1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.54
Shares Outstanding57,361,260
10 Day Avg. Volume741,774
30 Day Avg. Volume694,708
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.71
Price to Sales (P/S)162.41
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue95.86
Enterprise Value/Gross Profit-25.20
Enterprise Value/Ebitda-4.53
Forecast
1Y Price Target
$43.50Price Target Upside96.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.5
Revenue Forecast (FY)$9.38M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionAt‑home subcutaneous administration, the ability to pause treatment for vaccinations or procedures, and faster B‑cell recovery make obexelimab more patient‑friendly than intravenous options and could drive physician prescribing and patient uptake.
Pipeline Expansion And LifecycleDevelopment of a longer‑acting form of obex along with an oral CNS‑penetrant BTK inhibitor for progressive multiple sclerosis broadens the company’s autoimmune franchise and creates multiple potential commercial opportunities.
Regulatory OutlookPositive registrational Phase 3 results in IgG4‑related disease demonstrating reduced disease flares and a favorable safety profile increase the likelihood of regulatory approval in major markets.
Bears Say
Comparative Efficacy And Market PenetrationAlthough the Phase 3 trial met its primary endpoint, the results were perceived as less impressive versus a competing therapy, which may limit pricing power, market penetration, and investor enthusiasm.
Competitive ThreatsA competing cytolytic anti‑CD19 antibody with stronger efficacy could challenge obexelimab’s market positioning and erode potential market share despite obexelimab’s dosing and safety advantages.
Financing And Milestone RiskA portion of additional funding is contingent on regulatory and commercial milestones, creating execution and financing uncertainty that could pressure program timelines if targets are not met.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $6.11 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.27B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
Zenas BioPharma, Inc.’s upcoming earnings report date is May 14, 2026 which is in 48 days.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Mar 16, 2026. The company reported -$4.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$3.539.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate is -1.47.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 57,361,260 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$4.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -3.369%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.50 (96.30% Upside)
$43.50 (96.30% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.57%
12-Months-Change
Fundamentals
Return on Equity
-156.98%
Trailing 12-Months
Asset Growth
3.70%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$43.50
▲(96.30% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---